TY - JOUR
T1 - Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer
AU - Haroun, F.
AU - Al-Shaar, L.
AU - Habib, R. H.
AU - El-Saghir, N.
AU - Tfayli, A.
AU - Bazarbachi, A.
AU - Salem, Z.
AU - Shamseddine, A.
AU - Taher, A.
AU - Cascorbi, I.
AU - Zgheib, N. K.
N1 - Publisher Copyright:
© 2014 Springer-Verlag Berlin Heidelberg.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Purpose: The purpose of this study was to measure the frequency of three CYP2B6 [CYP2B6∗4 (rs2279343), CYP2B6∗5 (rs3211371) and CYP2B6∗9 (rs3745274)] alleles in patients with breast cancer receiving cyclophosphamide (CP) therapy and test whether these variants are predictors of CP-associated toxicity and efficacy. Methods: A total of 145 female breast cancer patients admitted to the American University of Beirut Medical Center for breast cancer-related therapy were included. Chart review was performed for collection of toxicity data. A time-to-event analysis was performed with a subset of 38 patients. Results: The minor allele frequencies of CYP2B6∗9, CYP2B6∗4 and CYP2B6∗5 were 0.27, 0.29 and 0.07, respectively. CYP2B6∗5/∗6,∗6/∗9 or∗6/∗6 haplotypes were associated with a significantly shorter time to recurrence of the disease. There were no significant associations with myelo-toxicity. Conclusions: This is the first report on the pharmacogenetic profile of patients with breast cancer and the therapeutic and myelo-toxic behavior of CP in women from an Arab Middle Eastern country. Our results show that genotyping for these CYP2B6 alleles does not help in personalizing therapy from a toxicity perspective, and the association of shorter survival in these subjects with homozygous variants is interesting yet insufficient to justify routine genotyping prior to therapy, or to consider using a higher CP dose. Larger future studies or meta-analyses will be needed to further clarify the potential implication of these genetic polymorphisms.
AB - Purpose: The purpose of this study was to measure the frequency of three CYP2B6 [CYP2B6∗4 (rs2279343), CYP2B6∗5 (rs3211371) and CYP2B6∗9 (rs3745274)] alleles in patients with breast cancer receiving cyclophosphamide (CP) therapy and test whether these variants are predictors of CP-associated toxicity and efficacy. Methods: A total of 145 female breast cancer patients admitted to the American University of Beirut Medical Center for breast cancer-related therapy were included. Chart review was performed for collection of toxicity data. A time-to-event analysis was performed with a subset of 38 patients. Results: The minor allele frequencies of CYP2B6∗9, CYP2B6∗4 and CYP2B6∗5 were 0.27, 0.29 and 0.07, respectively. CYP2B6∗5/∗6,∗6/∗9 or∗6/∗6 haplotypes were associated with a significantly shorter time to recurrence of the disease. There were no significant associations with myelo-toxicity. Conclusions: This is the first report on the pharmacogenetic profile of patients with breast cancer and the therapeutic and myelo-toxic behavior of CP in women from an Arab Middle Eastern country. Our results show that genotyping for these CYP2B6 alleles does not help in personalizing therapy from a toxicity perspective, and the association of shorter survival in these subjects with homozygous variants is interesting yet insufficient to justify routine genotyping prior to therapy, or to consider using a higher CP dose. Larger future studies or meta-analyses will be needed to further clarify the potential implication of these genetic polymorphisms.
UR - http://www.scopus.com/inward/record.url?scp=84925230990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925230990&partnerID=8YFLogxK
U2 - 10.1007/s00280-014-2632-4
DO - 10.1007/s00280-014-2632-4
M3 - Article
C2 - 25428516
AN - SCOPUS:84925230990
SN - 0344-5704
VL - 75
SP - 207
EP - 214
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 1
ER -